195 related articles for article (PubMed ID: 34903486)
1. Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight.
Mostafa T; Alghobary MF
Sex Med Rev; 2022 Jul; 10(3):392-402. PubMed ID: 34903486
[TBL] [Abstract][Full Text] [Related]
2. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
[TBL] [Abstract][Full Text] [Related]
3. Effect of Genetic Polymorphism on the Response to PDE5 Inhibitors in Patients With Erectile Dysfunction: A Systematic Review and a Critical Appraisal.
Mostafa T; Hassan A; Alghobary MF; Abdelrahman SH
Sex Med Rev; 2020 Oct; 8(4):573-585. PubMed ID: 32636154
[TBL] [Abstract][Full Text] [Related]
4. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
6. Oral phosphodiesterase type 5 inhibitors and male reproductive potential: an overview.
Mostafa T; Alghobary M; Hanafy NS; Abosief A
Sex Med Rev; 2023 Jun; 11(3):240-252. PubMed ID: 36990971
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
8. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
9. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
10. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.
Lombardo R; Tema G; De Nunzio C
Curr Drug Targets; 2021; 22(1):31-37. PubMed ID: 32981502
[TBL] [Abstract][Full Text] [Related]
13. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
14. Association between sexual activity-related death and non-prescription use of phosphodiesterase type 5 inhibitors.
Nagasawa S; Saka K; Yamagishi Y; Yajima D; Chiba F; Yamaguchi R; Torimitsu S; Iwase H
Leg Med (Tokyo); 2021 Feb; 48():101815. PubMed ID: 33264696
[TBL] [Abstract][Full Text] [Related]
15. Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis.
Abbasi B; Shaw NM; Lui JL; Hakam N; Nabavizadeh B; Breyer BN
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5721. PubMed ID: 37909414
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
[TBL] [Abstract][Full Text] [Related]
17. Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats.
Sheweita SA; Wally M; Hassan M
Oxid Med Cell Longev; 2016; 2016():4970906. PubMed ID: 27800121
[TBL] [Abstract][Full Text] [Related]
18. Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?
Mostafa T
Sex Med Rev; 2021 Jan; 9(1):15-22. PubMed ID: 33077403
[TBL] [Abstract][Full Text] [Related]
19. [Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].
Shodmonova ZR; Gafarov RR; Allazov SA; Giyasov SI
Urologiia; 2021 May; (2):135-140. PubMed ID: 33960173
[TBL] [Abstract][Full Text] [Related]
20. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients.
Lombardi G; Macchiarella A; Cecconi F; Del Popolo G
J Sex Med; 2009 May; 6(5):1248-58. PubMed ID: 19210710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
